Johansson S A, Andersson K E, Brattsand R, Gruvstad E, Hedner P
Eur J Clin Pharmacol. 1982;22(6):523-9. doi: 10.1007/BF00609625.
Topical anti-inflammatory (cutaneous "vasoconstriction") and systemic glucocorticoid (depression of plasma cortisol and changes in differential WBC count) potencies of the two glucocorticoids budesonide and beclomethasone dipropionate (BDP) were compared in human volunteers. After topical application, budesonide was 2-3 times more potent than BDP in inducing "vasoconstriction". After oral administration, on the other hand, budesonide was 2-4 times less potent than BDP in depressing plasma cortisol and changing the total or differential WBC. After inhalation, too, significant differences in favour of budesonide were noted, but the divergence between the drugs was less pronounced. The improved relationship between the topical and systemic glucocorticoid effects of budesonide makes it a promising alternative for aerosol treatment in asthma.
在人类志愿者中比较了两种糖皮质激素布地奈德和二丙酸倍氯米松(BDP)的局部抗炎(皮肤“血管收缩”)和全身糖皮质激素(血浆皮质醇降低和白细胞分类计数变化)效力。局部应用后,布地奈德在诱导“血管收缩”方面的效力比BDP高2至3倍。另一方面,口服给药后,布地奈德在降低血浆皮质醇和改变白细胞总数或分类方面的效力比BDP低2至4倍。吸入后也观察到有利于布地奈德的显著差异,但药物之间的差异不太明显。布地奈德局部和全身糖皮质激素作用之间改善的关系使其成为哮喘气雾剂治疗的有希望的替代药物。